LY6D and cancer: From proteins elevated in cancer, 17 had elevated expression in urothelial cancer of which, 9 (16.1%) were elevated only in urothelial cancer (KRT7, GSTM1, HPGD, S100P, DHRS2, GDPD3, KRT23, TINAGL1, PADI3), while 8 (14.3%) in addition to urothelial cancer, were elevated in some other cancer too (SNCG, KRT13, KRT20, HSD17B2, FABP5, LY6D, INA, ANXA10).